NCT02441465View on ClinicalTrials.gov

Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 13, 2015

Primary Completion Date

August 18, 2016

Study Completion Date

January 9, 2017

Conditions
Malignant Melanoma, Cancer
Interventions
DRUG

Vemurafenib

Oral vemurafenib will be administered at a dose of 960 milligrams BID from Day 1 to Day 28.

DRUG

14C-Labeled Vemurafenib

IV infusion of 18.5 kilobecquerel (kBq) of 14C-labeled vemurafenib (3 milliliters \[mL\], which corresponds to a dose of 20 micrograms \[mcg\] of vemurafenib) on Day 21 (immediately after the morning oral dose of vemurafenib).

Trial Locations (1)

H-1134

Magyar Honvedseg Egeszsegugyi Kozpont, Budapest

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02441465 - Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies | Biotech Hunter | Biotech Hunter